Chlorobutanol as a Preservative in Injectables, Eye Drops, and Nasal Sprays

27-07-2026

Introduction

Multi-dose pharmaceutical products face a persistent formulation challenge: every time a vial, bottle, or spray is opened, there is an opportunity for microbial contamination. Antimicrobial preservatives exist to solve this problem, and chlorobutanol has been one of the most consistently used preservatives in this category for more than a century. This article looks at how chlorobutanol actually works, why it remains a preferred choice in specific dosage forms, and how it compares to some of the alternatives formulators consider.

How Chlorobutanol Works as an Antimicrobial

Chlorobutanol's antimicrobial action comes from its ability to disrupt the lipid bilayer that makes up microbial cell membranes. As it penetrates the membrane structure, it increases membrane permeability, which ultimately leads to cell death. This mechanism gives it broad spectrum activity against both gram positive and gram negative bacteria, along with activity against certain fungi, without relying on the surfactant based mechanism that some other preservative classes use.

This mode of action is part of why chlorobutanol performs reliably across a range of dosage forms and formulation environments, since it does not depend on interacting with the formulation the way a surfactant preservative might.

Chlorobutanol in Injectable Formulations

In parenteral formulations, chlorobutanol is used as an antibacterial preservative at concentrations up to about 0.5 percent weight by volume. It has a long history of use in multi-dose injectable products, including certain epinephrine solutions and posterior pituitary extract formulations, where repeated needle access into the same vial creates ongoing contamination risk that a preservative needs to manage across the product's in use shelf life.

One formulation advantage frequently cited for chlorobutanol in this context is its comparatively low tendency to cause protein aggregation. In biologic and protein based injectable formulations, preservative induced aggregation is a real stability concern, and chlorobutanol has been shown to induce less aggregation than several commonly used alternatives, extending the practical shelf life of sensitive protein therapeutics.

Chlorobutanol in Ophthalmic Preparations

Eye drops represent one of the largest and longest standing use cases for chlorobutanol. It is widely used in ophthalmic preparations, including formulations intended for conditions such as miosis. Despite some animal studies suggesting potential effects on ocular tissue at certain exposure levels, decades of widespread clinical use have been associated with a low incidence of adverse reactions in practice.

Comparative data has also shown that chlorobutanol supports meaningfully longer corneal epithelial cell survival compared to some alternative ophthalmic preservatives such as benzalkonium chloride, which is one reason it remains a formulation option even as newer preservative systems have entered the ophthalmic market.

Chlorobutanol in Nasal Sprays

Chlorobutanol is also used in nasal formulations, including intranasal calcitonin products, generally at concentrations between roughly 0.25 and 0.4 percent weight by weight. In this category, one advantage noted in formulation literature is that chlorobutanol tends to cause less nasal irritation compared to some alternative preservatives, such as benzalkonium chloride, which has in some cases been associated with aggravated rhinitis or allergic type reactions in sensitive patients.

Nasal formulations using chlorobutanol are also typically formulated at a controlled pH, often in the range of 3.5 to 5.5, since preservative activity and formulation stability are both influenced by pH, and maintaining an appropriate isotonicity is important to avoid irritating the nasal mucosa.

Chlorobutanol in Ear Drops and Dental Preparations

Beyond injectables, ophthalmics, and nasal sprays, chlorobutanol also appears in otic (ear) preparations and dental formulations such as mouthwashes. In dental applications, it offers a secondary benefit as a mild local anesthetic, in addition to its primary antimicrobial preservative function, which has supported its long term use in this category.

How Chlorobutanol Compares to Other Preservatives

Formulators evaluating preservative options for protein based or biologic formulations sometimes reference a general ranking of protein aggregation potential across common preservatives, with chlorobutanol typically inducing less aggregation than m-cresol, phenol, benzyl alcohol, and phenoxyethanol. This makes it a relevant option specifically for formulations where protein stability is a primary formulation concern, in addition to its established track record in traditional small molecule injectable, ophthalmic, and nasal products.

That said, preservative selection always depends on the full formulation context, including the active ingredient, target route of administration, required antimicrobial efficacy testing outcomes, and regulatory expectations in the target market.

Sourcing Considerations for Preservative Grade Chlorobutanol

Since chlorobutanol performs a functional, safety critical role across these dosage forms, sourcing decisions should prioritize:

Verified pharmacopeial compliance (USP, EP, BP, IP, or JP depending on target market)
Confirmed form (anhydrous or hemihydrate) matching your validated formulation
Documented purity and related substances testing on the certificate of analysis
Consistent particle characteristics for reliable dissolution and blending behavior

Sourcing platforms such as Clyzo that list chlorobutanol excipient with supplier specific documentation can help formulators compare options against these criteria before finalizing a supply source.

Common Questions About Chlorobutanol as a Preservative

Why is chlorobutanol still used when newer preservatives are available?

It offers a well established safety and efficacy track record across injectable, ophthalmic, and nasal formulations, along with specific advantages such as lower protein aggregation potential and generally lower irritation in nasal applications compared to some alternatives.

Is chlorobutanol safe for long term use in eye drops?

It has a long history of use in ophthalmic products with a low reported rate of adverse reactions in practice, although formulation concentration and patient specific sensitivity should always be considered by the prescribing formulation's safety data.

What concentration of chlorobutanol is typically used as a preservative?

Most formulations use chlorobutanol at approximately 0.5 percent, with nasal formulations sometimes using a slightly lower range of about 0.25 to 0.4 percent.

Does chlorobutanol work well in biologic or protein based formulations?

Yes, it is often favored in this context because it tends to induce less protein aggregation than several other common preservatives, which helps maintain the stability of sensitive protein therapeutics over their shelf life.

Conclusion

Chlorobutanol's continued use across injectable, ophthalmic, nasal, and dental formulations reflects a genuinely favorable balance of broad spectrum antimicrobial activity, low irritation potential, and compatibility with sensitive formulations, including protein based biologics. For formulators evaluating preservative systems, chlorobutanol remains a proven option worth comparing directly against newer alternatives on a formulation specific basis.

Excipient Suppliers India GMP Certified Injectable Excipients Pharmaceutical Excipients Pharmaceutical Grade Pharmaceutical Manufacturing Preservatives Regulatory Compliance Chlorobutanol Ophthalmic Formulations

Vaccine Excipients Oral Topical Biopharma

Ethanol 96% v/v for pharmaceutical excipients (Ph.... ... Ethanol 96% v/v for pharmaceutical excipients (Ph.Eur., BP, USP IPEC Grade) | Clyzo Read more

14-08-2026